Newstral
Biogen
- Biosimilar Launch and Approval Updates – Tyenne® (tocilizumab-aazg), Xlucane™ (ranibizumab), Hercessi™ (trastuzumab-strf)jdsupra.com
- Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigationjdsupra.com
- Pfizer On The New Lows List. Big Dividend Fails To Attract Buyers.Forbes
- Genentech and Dr. Reddy’s Settle BPCIA Litigation Against Proposed Rituxan Biosimilar DRL_RIjdsupra.com
- $158,000 ALS drug pulled from market after failing in large clinical trialArs Technica
- TF.D. Flam: Do you really want to find out if you’ll get Alzheimer’s?twincities.com
- New Non-Opioid Pain Meds Hold Promise, But Face Clinical Development And Insurer ChallengesForbes
- Fresenius Kabi Announces FDA Approval of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRAjdsupra.com
- Fresenius Kabi’s Actemra® biosimilar Tyenne® (tocilizumab-aazg) Approved in the U.S.jdsupra.com
- What Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAForbes
- FDA delays action on closely watched Alzheimer’s drugThe New York Times
- Genentech and Partners Voluntarily Dismiss IPR Appeals Related to Genentech’s ACTEMRA® (Tocilizumab)jdsupra.com
- Chugai, Genentech, and Hoffmann-La Roche Dismiss Appeals of Actemra® Patent IPR Final Written Decisionsjdsupra.com
- FDA approves first drug to prevent severe food allergy reactionsUSA today
- Celltrion Submits an aBLA for Actemra® (tocilizumab) Proposed Biosimilar CT-P47jdsupra.com
- Alzheimer’s Drug Aduhelm Went From Being Hailed A “Game Changer” To Becoming A DudForbes
- Five takeaways from POLITICO’s ‘How Fast Can We Solve Alzheimer’s’ EventPOLITICO
- Alzheimer’s program renewal on the way, lawmakers sayPOLITICO
- Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandalArs Technica
- Biogen Abandons Its Controversial Alzheimer’s Drug AduhelmWRAL
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.